October 30, 2012
Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

December 3, 2010
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease

November 30, 2010
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1 NP001 Study in the Treatment of Amyotrophic Lateral Sclerosis (ALS)

November 5, 2010
Neuraltus Pharmaceuticals Awarded $733,437 Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)

October 4, 2010
Neuraltus Pharmaceuticals Announces Last Patient Out for Studies in ALS and Dyskinesias Associated with the Treatment of Parkinson's Disease

February 8, 2010
Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO

March 26, 2009
Neuraltus Pharmaceuticals Raises $17 Million Series A Funding

Links to News Coverage

September 2, 2011
Patients enlist in fight against ALS
Social media aids Neuraltus drug
http://www.bizjournals.com/sanfrancisco/print-edition/2011/09/02/patients-enlist-in-fight-against-als.html

August 30, 2011
Neuraltus ALS drug wins fast track, orphan status
http://www.bizjournals.com/sanfrancisco/blog/biotech/2011/08/neuraltus-als-lou-gehrig.html?s=print